Apixaban (Eliquis) prevents more atrial fibrillation strokes than warfarin — March FDA approval expected

A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at:

Apixaban Superior to Warfarin for Atrial Fibrillation Stroke Prevention

The FDA has just announced expedited review of Eliquis for atrial fibrillation stroke prevention, with approval expected by March 28, 2012.